Status:
COMPLETED
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Multiple Myeloma
Eligibility:
All Genders
20+ years
Brief Summary
The purpose of this observational study is to assess HRQoL in relapsed and/or refractory multiple myeloma (RRMM) participants who have previously received a proteasome inhibitor, an immunomodulatory a...
Eligibility Criteria
Inclusion
- Must have sufficient command of the Japanese language to understand the study instructions and requirements
- Must be a resident of Japan
- Must have received prior treatment with:
- a proteasome inhibitor,
- an immunomodulatory agent, and
- an anti-CD38 antibody Subjects must be either 2-4 months, 5-7 months, or 8-11 months post triple class therapy exposure at time of consent
- Subject must be diagnosed with multiple myeloma
Exclusion
- Participants enrolled in a clinical trial that includes at least one novel/ experimental agent at the point of questionnaire completion
- Other protocol-defined inclusion/exclusion criteria apply.
Key Trial Info
Start Date :
February 22 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 3 2022
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT05217082
Start Date
February 22 2022
End Date
August 3 2022
Last Update
June 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0001
Morrisville, North Carolina, United States, 27560